MIAS Pharma Limited

About MIAS Pharma Limited

MIAS Pharma Limited operates in the Other / Uncategorized space and is among the firms Bracken expects to track at SNMMI 2026.

Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.

What we're seeing

• FierceBiotech · 2026-03-06
  Mias Pharma Limited appoints new Chief Medical Officer ahead of pivotal trial
  The work builds on more than a decade of radiochemistry collaboration.
• BioPharma Reporter · 2026-08-25
  Mias Pharma Limited signs supply agreement to support late-stage trials
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• Reuters Health · 2026-09-04
  Mias Pharma Limited expands cyclotron capacity to meet Lu-177 demand
  Details remain limited but analysts read the move as a positioning play ahead of pivotal data.
• Endpoints News · 2026-06-27
  Mias Pharma Limited announces Phase II readout for lead theranostic candidate
  The announcement comes amid tightening Mo-99 and Lu-177 supply.

Mocked while we wire the Exa integration. Headlines are illustrative.

What we expect to see at the booth

Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.